Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study.

Salvador L, Singaravelu G, Harley CB, Flom P, Suram A, Raffaele JM.

Rejuvenation Res. 2016 Dec;19(6):478-484. Epub 2016 Mar 30.

2.

Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study.

Dow CT, Harley CB.

Clin Ophthalmol. 2016 Jan 28;10:243-9. doi: 10.2147/OPTH.S100042. eCollection 2016.

3.

Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management.

Ip FC, Ng YP, An HJ, Dai Y, Pang HH, Hu YQ, Chin AC, Harley CB, Wong YH, Ip NY.

Neurosignals. 2014;22(1):52-63. doi: 10.1159/000365290. Epub 2014 Jul 31.

4.

A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response.

Harley CB, Liu W, Flom PL, Raffaele JM.

Rejuvenation Res. 2013 Oct;16(5):386-95. doi: 10.1089/rej.2013.1430.

PMID:
23808324
5.

A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis.

Le Saux CJ, Davy P, Brampton C, Ahuja SS, Fauce S, Shivshankar P, Nguyen H, Ramaseshan M, Tressler R, Pirot Z, Harley CB, Allsopp R.

PLoS One. 2013;8(3):e58423. doi: 10.1371/journal.pone.0058423. Epub 2013 Mar 14.

6.

Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types.

Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, Chin AC, Harley CB, Ip NY, Wong YH.

Planta Med. 2012 Jan;78(2):115-21. doi: 10.1055/s-0031-1280346. Epub 2011 Nov 14.

PMID:
22083896
7.

The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence.

Bernardes de Jesus B, Schneeberger K, Vera E, Tejera A, Harley CB, Blasco MA.

Aging Cell. 2011 Aug;10(4):604-21. doi: 10.1111/j.1474-9726.2011.00700.x. Epub 2011 Apr 14.

8.

Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.

Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L, Clarke I, Harley CB, Tressler R, Malkin D, Walker E, Kaplan DR, Dirks P, Tabori U.

Clin Cancer Res. 2011 Jan 1;17(1):111-21. doi: 10.1158/1078-0432.CCR-10-2075.

9.

Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths.

Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A.

Nat Protoc. 2010 Sep;5(9):1596-607. doi: 10.1038/nprot.2010.124. Epub 2010 Sep 2.

PMID:
21085125
10.

In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator.

Zhu J, Lee S, Ho MK, Hu Y, Pang H, Ip FC, Chin AC, Harley CB, Ip NY, Wong YH.

Drug Metab Pharmacokinet. 2010;25(5):477-86. Epub 2010 Sep 22.

11.

A natural product telomerase activator as part of a health maintenance program.

Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM.

Rejuvenation Res. 2011 Feb;14(1):45-56. doi: 10.1089/rej.2010.1085. Epub 2010 Sep 7.

12.

Imetelstat (GRN163L)--telomerase-based cancer therapy.

Röth A, Harley CB, Baerlocher GM.

Recent Results Cancer Res. 2010;184:221-34. doi: 10.1007/978-3-642-01222-8_16. Review.

PMID:
20072842
13.

Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB.

J Immunol. 2008 Nov 15;181(10):7400-6.

14.

Telomerase and cancer therapeutics.

Harley CB.

Nat Rev Cancer. 2008 Mar;8(3):167-79. doi: 10.1038/nrc2275. Review.

PMID:
18256617
15.

Adenoviral human telomerase reverse transcriptase dramatically improves ischemic wound healing without detrimental immune response in an aged rabbit model.

Mogford JE, Liu WR, Reid R, Chiu CP, Said H, Chen SJ, Harley CB, Mustoe TA.

Hum Gene Ther. 2006 Jun;17(6):651-60.

PMID:
16776573
16.

Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.

Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL.

Hepatology. 2005 Nov;42(5):1127-36.

PMID:
16114043
17.

Telomerase therapeutics for degenerative diseases.

Harley CB.

Curr Mol Med. 2005 Mar;5(2):205-11. Review.

PMID:
15974874
18.

Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.

Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM.

Oncogene. 2005 Aug 4;24(33):5262-8.

PMID:
15940257
19.

The aging factor in health and disease: the promise of basic research on aging.

Butler RN, Warner HR, Williams TF, Austad SN, Brody JA, Campisi J, Cerami A, Cohen G, Cristofalo VJ, Drachman DA, Finch CE, Fridovich I, Harley CB, Havlik RJ, Martin GM, Miller RA, Olshansky SJ, Pereira-Smith OM, Smith JR, Sprott RL, West MD, Wilmoth JR, Wright WE.

Aging Clin Exp Res. 2004 Apr;16(2):104-11; discussion 111-2. Review. No abstract available.

PMID:
15195984
20.

Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms.

O'Sullivan JN, Finley JC, Risques RA, Shen WT, Gollahon KA, Moskovitz AH, Gryaznov S, Harley CB, Rabinovitch PS.

Cytometry A. 2004 Apr;58(2):120-31.

21.

A novel telomerase template antagonist (GRN163) as a potential anticancer agent.

Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin AC, Harley CB, Gryaznov S.

Cancer Res. 2003 Jul 15;63(14):3931-9.

22.

Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells.

Allsopp RC, Morin GB, Horner JW, DePinho R, Harley CB, Weissman IL.

Nat Med. 2003 Apr;9(4):369-71. No abstract available.

PMID:
12669037
23.

Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation.

Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL.

Blood. 2003 Jul 15;102(2):517-20. Epub 2003 Mar 27.

24.

Cancer treatment by telomerase inhibitors: predictions by a kinetic model.

Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS.

Math Biosci. 2003 Feb;181(2):209-21.

PMID:
12445762
25.

Cancer cell dynamics in presence of telomerase inhibitors: analysis of in vitro data.

Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS.

J Theor Biol. 2002 Nov 21;219(2):225-33.

PMID:
12413877
26.

Telomerase is not an oncogene.

Harley CB.

Oncogene. 2002 Jan 21;21(4):494-502. Review.

27.

Telomerase and Cell Immortality: Applications in Research and Medicine.

Harley CB.

ScientificWorldJournal. 2001 Nov 2;1:115. doi: 10.1100/tsw.2001.217. eCollection 2001. No abstract available.

28.

Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase.

Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T.

Cancer Res. 2001 Apr 1;61(7):3053-61.

29.

How long should telomeres be?

Aviv A, Harley CB.

Curr Hypertens Rep. 2001 Apr;3(2):145-51. Review.

PMID:
11276397
30.

Telomerase expression restores dermal integrity to in vitro-aged fibroblasts in a reconstituted skin model.

Funk WD, Wang CK, Shelton DN, Harley CB, Pagon GD, Hoeffler WK.

Exp Cell Res. 2000 Aug 1;258(2):270-8.

PMID:
10896778
31.

Laying hold on eternal life?

Wilmut I, Clark J, Harley CB.

Nat Biotechnol. 2000 Jun;18(6):599-600. No abstract available.

PMID:
10835593
32.

Telomere-dependent senescence.

Kipling D, Wynford-Thomas D, Jones CJ, Akbar A, Aspinall R, Bacchetti S, Blasco MA, Broccoli D, DePinho RA, Edwards DR, Effros RB, Harley CB, Lansdorp PM, Linskens MH, Prowse KR, Newbold RF, Olovnikov AM, Parkinson EK, Pawelec G, Pontén J, Shall S, Zijlmans M, Faragher RG.

Nat Biotechnol. 1999 Apr;17(4):313-4. No abstract available.

PMID:
10207859
33.

Extension of life-span by introduction of telomerase into normal human cells.

Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE.

Science. 1998 Jan 16;279(5349):349-52.

34.

Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT.

Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB.

Nat Genet. 1997 Dec;17(4):498-502.

PMID:
9398860
35.

Telomerase catalytic subunit homologs from fission yeast and human.

Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR.

Science. 1997 Aug 15;277(5328):955-9.

36.

Replicative senescence and cell immortality: the role of telomeres and telomerase.

Chiu CP, Harley CB.

Proc Soc Exp Biol Med. 1997 Feb;214(2):99-106. Review.

PMID:
9034126
37.

Human ageing and telomeres.

Harley CB.

Ciba Found Symp. 1997;211:129-39; discussion 139-44. Review.

PMID:
9524755
38.

Telomerase, checkpoints and cancer.

Harley CB, Sherwood SW.

Cancer Surv. 1997;29:263-84. Review.

PMID:
9338104
39.

Aging of cultured human skin fibroblasts.

Harley CB, Sherwood SW.

Methods Mol Biol. 1997;75:23-30. Review. No abstract available.

PMID:
9276258
40.

Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis.

Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, Harley CB, Villeponteau B, West MD, Giorgi JV.

AIDS. 1996 Jul;10(8):F17-22.

PMID:
8828735
41.

Phosphorylation of human pleckstrin on Ser-113 and Ser-117 by protein kinase C.

Craig KL, Harley CB.

Biochem J. 1996 Mar 15;314 ( Pt 3):937-42.

42.

Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow.

Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM.

Stem Cells. 1996 Mar;14(2):239-48.

43.

Telomerase and cancer.

Harley CB, Kim NW.

Important Adv Oncol. 1996:57-67. Review.

PMID:
8791128
44.

Telomere length and replicative aging in human vascular tissues.

Chang E, Harley CB.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11190-4.

45.

Telomerase activity in normal and malignant murine tissues.

Chadeneau C, Siegel P, Harley CB, Muller WJ, Bacchetti S.

Oncogene. 1995 Sep 7;11(5):893-8.

PMID:
7675448
46.

Telomere shortening is associated with cell division in vitro and in vivo.

Allsopp RC, Chang E, Kashefi-Aazam M, Rogaev EI, Piatyszek MA, Shay JW, Harley CB.

Exp Cell Res. 1995 Sep;220(1):194-200.

PMID:
7664836
47.

Evidence for a critical telomere length in senescent human fibroblasts.

Allsopp RC, Harley CB.

Exp Cell Res. 1995 Jul;219(1):130-6.

PMID:
7628529
48.

Response.

Kim NW, Harley CB, Prowse KR, Weinrich SL, Piatyszek MA, Wright WE, Shay JW.

Science. 1995 May 26;268(5214):1116-7. No abstract available.

PMID:
17840613
49.

Telomerase activity in normal leukocytes and in hematologic malignancies.

Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S.

Blood. 1995 May 1;85(9):2315-20.

50.

Telomeres and telomerase in aging and cancer.

Harley CB, Villeponteau B.

Curr Opin Genet Dev. 1995 Apr;5(2):249-55. Review.

PMID:
7613096

Supplemental Content

Loading ...
Support Center